Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance
L Aagaard,
C E Hallgreen
,
E H Hansen
10
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Anti-obesity
100%
Adverse Events
100%
Postmarketing
100%
Serious Adverse Events
100%
EudraVigilance
100%
Adverse Event Reporting
50%
EudraVigilance Database
30%
Anatomical Therapeutic Chemical
20%
System Organ Class
20%
Europe
20%
Systematic Monitoring
10%
Neuropsychiatric Adverse Events
10%
Orlistat
10%
Adverse Event Data
10%
Event Type
10%
Chemical Groups
10%
Spontaneous Reports
10%
Rimonabant
10%
Cardiac Adverse Events
10%
Cardiac Disease
10%
Psychiatric Disorders
10%
Female Adults
10%
New Medicines
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Rimonabant
4%
Tetrahydrolipstatin
4%